

Financial news for AMPE dated on 2020-05-22: Ampio Says Filed IND Applications For Ampion

Financial news for AMPE dated on 2020-05-11: Ampio Reports Acceptance Of Publication On The Potential Benefits Of Nebulized Ampion For COVID-19 Coronavirus Patients

Financial news for AMPE dated on 2020-05-11: Ampio Pharma Reports Acceptance Of Publication On Potential Benefits Of Nebulized Ampion For Coronavirus Patients

Financial news for AMPE dated on 2020-04-02: Ampio Pharma Highlights FDA Application For Ampion To Treat Coronavirus-Induced Acute Respiratory Distress Syndrome Featured In FOX News Video

Financial news for AMPE dated on 2020-03-24: Ampio Suspends Patient Enrollment In Phase 3 Study Of Ampion For Severe Osteoarthritis Of The Knee And Explores Other Options To Complete Trial As A Result Of Coronavirus Concerns

Financial news for AMPE dated on 2020-03-24: Ampio Says Is Preparing Expanded Access FDA Protocol To 'Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with' Coronavirus

Financial news for AMPE dated on 2020-02-21: Ampio Pharma 10-K Just Out; Includes Message About Co.'s Independent Registered Public Accounting Firm Having Expressed Substantial Doubt As To Co.'s Ability To Continue As A Going Concern

Financial news for AMPE dated on 2019-12-19: Roth Capital Initiates Coverage On Ampio Pharmaceuticals with Buy Rating, Announces \$4 Price Target

Financial news for AMPE dated on 2019-12-18: Ampio Pharmaceuticals shares are trading higher after Roth Capital Partners initiated coverage on the stock with a Buy rating.

Financial news for AMPE dated on 2019-12-18: Roth Capital Partners Initiates Coverage On Ampio Pharmaceuticals With Buy Rating, Says Mid-2020 Release Of AP-013 Data Will Be A 'Positive, Material Investment Catalyst'

Financial news for AMPE dated on 2019-10-10: Ampio Pharma Offers Update On Continued Progress Of AP-013 Phase 3 Trial, Manufacturing Facility

Financial news for AMPE dated on 2019-09-17: UPDATE: Ampio Says Co. Consented/Enrolled 661 Patients Of Which 423 Have Been Injected, Added 52 Patients Approved For Injection

Financial news for AMPE dated on 2019-09-17: Ampio Pharma Reports FDA Gave Written Guidance That Prior AP-003-A Study Qualifies As Pivotal Trial, Successful Passing Of Current Study Would Support Filing Of Biologics License Application

Financial news for AMPE dated on 2019-08-19: ThinkEquity Initiates Coverage On Ampio Pharmaceuticals With Buy Rating And \$5 Price Target

Financial news for AMPE dated on 2019-07-25: Ampio Pharma Offers Update On Special Protocol Assessment Trial

Financial news for AMPE dated on 2019-06-18: 60 Biggest Movers From Yesterday

Financial news for AMPE dated on 2019-06-17: Mid-Afternoon Market Update: Crude Oil Down 1.5%; C&J Energy Services Shares Spike Higher

Financial news for AMPE dated on 2019-06-17: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for AMPE dated on 2019-06-17: Mid-Day Market Update: Sotheby's Jumps On Acquisition News; Flex Pharma Shares Slide

Financial news for AMPE dated on 2019-06-17: Mid-Morning Market Update: Markets Open Higher; Pfizer To Acquire Array BioPharma For \$48/Share

Financial news for AMPE dated on 2019-06-17: Ampio Pharmaceuticals, Inc. shares are trading lower after the company priced a 25.32 million share common stock offering at \$0.40 per share.

Financial news for AMPE dated on 2019-06-17: Ampio Pharmaceuticals Prices 25.32M Share Common Stock Offering At \$0.40/Share

Financial news for AMPE dated on 2019-06-17: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for AMPE dated on 2019-06-17: A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Economic Data

Financial news for AMPE dated on 2019-06-17: 46 Biggest Movers From Friday

Financial news for AMPE dated on 2019-06-17: 5 Stocks To Watch For June 17, 2019

Financial news for AMPE dated on 2019-06-14: Ampio Pharmaceuticals shares are trading lower after the company reported a common stock offering with no disclosed size.

Financial news for AMPE dated on 2019-06-14: Ampio Pharmaceuticals Reports Common Stock Offering, No Size Disclosed

Financial news for AMPE dated on 2019-06-14: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for AMPE dated on 2019-06-14: Ampio Pharmaceuticals Shares Resume Trading; Currently At \$0.92/Share

Financial news for AMPE dated on 2019-06-14: Ampio Pharmaceuticals Shares Halted At \$1.05; After Opening Shares Traded In Range Of \$1.05-\$1.30/Share

Financial news for AMPE dated on 2019-06-14: Ampio Pharmaceuticals Resume Trade At \$1.07 Shares Then Halted For A Second Time

Financial news for AMPE dated on 2019-06-14: Ampio Pharmaceuticals Halted On Circuit Breaker; Shares Halted At \$0.92, Up 46.03% In The Session

Financial news for AMPE dated on 2019-06-14: Ampio Pharmaceuticals shares are trading higher after the company announced FDA approval of its special protocol assessment.

Financial news for AMPE dated on 2019-06-14: Ampio Pharma Announces FDA Approval of the Company's Special Protocol Assessment

Financial news for AMPE dated on 2019-05-22: Ampio Pharma Offers Corporate, Clinical, Regulatory Updates

Financial news for AMPE dated on 2019-05-21: Ampio Pharmaceuticals, Inc. Option Alert: Jan, 2021 \$1 Calls at the Ask: 800 @ \$0.3 vs 1169 OI; Ref=\$0.5001

Financial news for AMPE dated on 2019-04-29: Ampio Pharmaceuticals shares are trading lower after the company announced the FDA recommended that the company not start their confirmatory trial without obtaining FDA concurrence on the trial design.

Financial news for AMPE dated on 2019-04-29: Ampio Pharma Receives Notice from the FDA to Not Start its Confirmatory Trial Without Obtaining FDA Concurrence on Trial Design

Financial news for AMPE dated on 2019-04-15: Ampio Pharmaceuticals May Offer, Sell Shares Of Common Stock From Time To Time Up To \$24.65M Through Canaccord, Acting As Sales Agent

Financial news for AMPE dated on 2019-03-27: The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO

Financial news for AMPE dated on 2019-03-27: Ampio Pharmaceuticals Announces Resubmission of Special Protocol Assessment with FDA for a Confirmatory Phase III Clinical Trial of Ampion for Treatment of Patients Afflicted with Osteoarthritis of the Knee

Financial news for AMPE dated on 2019-03-06: Ampio Pharma Reports FDA Provided Guidance Co. 'should complete an additional trial of Kellgren Lawrence Grade 4 osteoarthritis of the knee patients with concurrent controls that would be carried out under a Special Protocol Assessment'

Financial news for AMPE dated on 2019-02-06: Ampio Receives Initial Response From FDA Regarding Co.'s Proposed Trial

Financial news for AMPE dated on 2018-12-13: Ampio Pharmaceuticals shares are trading down 23% premarket after the Co announced that the FDA will require a new clinical trial of Ampion, the Co's lead drug for the treatment of severe osteoarthritis of the knee, to support its marketing application.

Financial news for AMPE dated on 2018-12-13: Ampio Says FDA's Office of Tissue and Advanced Therapies Met With Co. About Ampion, Provide Guidance Co. Should Complete Added Trial Of KL4 Osteoarthritis Patients

Financial news for AMPE dated on 2018-11-26: Ampio Pharma Announces the FDA's Office of Tissue and Advanced Therapies Will Provide Guidance by Mid-December if Ampio's Trial Portion of Ampion BLA is Complete Or Will Require an Additional Trial

Financial news for AMPE dated on 2018-11-08: 88 Biggest Movers From Yesterday

Financial news for AMPE dated on 2018-11-07: 70 Stocks Moving In Wednesday's Mid-Day Session

Financial news for AMPE dated on 2018-11-07: Ampio Earlier Announced FDA Has Accepted A Type C Meeting Proposal From Co. And Scheduled Meeting Before End Of November

Financial news for AMPE dated on 2018-11-07: Ampio Pharmaceuticals shares are trading higher after the FDA accepted a meeting proposal to resolve a dispute regarding the acceptability of a trial for one of two pivotal trials required to file a biologics license application.

Financial news for AMPE dated on 2018-09-20: 'The \$GALT stock promoters (many of the same involved with the \$AMPE pump and dump) have been salivating in anticipation of these meaningless single-arm combo data. Day traders enjoy!' -Tweet From STAT News' Adam Feuerstein

Financial news for AMPE dated on 2018-09-04: Ampio Pharmaceuticals' Chief Scientific Officer David Var-Or Retiring Effective September 30th

Financial news for AMPE dated on 2018-08-10: Stocks Which Set New 52-Week Low Yesterday, August 9th

Financial news for AMPE dated on 2018-08-10: 77 Biggest Movers From Yesterday

Financial news for AMPE dated on 2018-08-09: Mid-Afternoon Market Update: Yelp Jumps Following Strong Q2 Earnings; e.l.f. Beauty Shares Slide

Financial news for AMPE dated on 2018-08-09: 68 Stocks Moving In Thursday's Mid-Day Session

Financial news for AMPE dated on 2018-08-09: Mid-Day Market Update: iPass Drops After Q2 Results; Belmond Shares Surge

Financial news for AMPE dated on 2018-08-09: Ampio Pharmaceuticals shares are trading 38% lower to \$0.38 after the company announced public offering of 20M shares at \$0.40/share.

Financial news for AMPE dated on 2018-08-09: Mid-Morning Market Update: Markets Edge Higher; Viacom Profit Beats Views

Financial news for AMPE dated on 2018-08-09: Ampio Pharma Prices 20M Share Common Stock Offering At \$0.40/Share

Financial news for AMPE dated on 2018-08-09: The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings

Financial news for AMPE dated on 2018-08-09: 40 Stocks Moving In Thursday's Pre-Market Session

Financial news for AMPE dated on 2018-08-09: 85 Biggest Movers From Yesterday

Financial news for AMPE dated on 2018-08-08: Ampio Pharma Announces Common Stock Offering, No Size Disclosed

Financial news for AMPE dated on 2018-08-08: Mid-Afternoon Market Update: Crude Oil Down 3.5%; Endo International Shares Surge After Strong Q2 Results

Financial news for AMPE dated on 2018-08-08: 68 Stocks Moving In Wednesday's Mid-Day Session

Financial news for AMPE dated on 2018-08-08: Mid-Day Market Update: 3D Systems Climbs On Earnings Beat; Core Molding Technologies Shares Drop

Financial news for AMPE dated on 2018-08-08: Mid-Morning Market Update: Markets Edge Lower; CVS Health Profit Tops Expectations

Financial news for AMPE dated on 2018-08-07: Ampio Pharma shares down 61% after the FDA said the company's trial for AP-0003-C was not adequate. The FDA is recommending Ampio performs a randomized trial

Financial news for AMPE dated on 2018-08-07: Ampio Pharmaceuticals 8-K Indicates FDA Said In Response Letter That It Does Not Consider AP-0003-C Trial To Be Adequate And Well-Controlled Clinical Trial And Recommended Co. Performs Randomized Trial With Concurrent Trial; Shares Down 54.7% After Hours

Financial news for AMPE dated on 2018-08-07: 36 Stocks Moving In Tuesday's Pre-Market Session

Financial news for AMPE dated on 2018-08-07: 52 Biggest Movers From Yesterday

Financial news for AMPE dated on 2018-08-06: 66 Biggest Movers From Friday

Financial news for AMPE dated on 2018-07-27: 'Someone is paying for a new \$AMPE stock promotion campaign on Twitter, Seeking Alpha, message boards and web sites like below:'-STAT's Adam Feuerstein Tweets

Financial news for AMPE dated on 2018-07-27: 36 Stocks Moving In Friday's Pre-Market Session

Financial news for AMPE dated on 2018-07-24: 38 Biggest Movers From Yesterday

Financial news for AMPE dated on 2018-07-23: 34 Stocks Moving In Monday's Mid-Day Session

Financial news for AMPE dated on 2018-07-23: 41 Biggest Movers From Friday

Financial news for AMPE dated on 2018-06-22: Ampio Pharmaceuticals Shares Up 15.7% For Session Despite No Company-Specific News Or Fundamental Catalyst To Justify Price Action; Watch For Technical Indicators And Price Action

Financial news for AMPE dated on 2018-06-05: Ampio Announces 2 Peer-Reviewed Articles ON Clinical Application Of Ampion

Financial news for AMPE dated on 2018-05-30: 42 Biggest Movers From Yesterday

Financial news for AMPE dated on 2018-05-29: 37 Stocks Moving In Tuesday's Mid-Day Session

Financial news for AMPE dated on 2018-05-29: Ampio Awarded U.S. Patent For Treatment Of Joint Conditions That Provides Method Protection Until 2035 For Multiple Injections Of Ampion

Financial news for AMPE dated on 2018-05-14: UPDATE: Ampio Says Is Actively Pursuing Endeavors To Strengthen Its Balance Sheet

Financial news for AMPE dated on 2018-05-14: UPDATE: Ampio Says Co. Has Hired Added Internal Staff Dedicated Solely To Supporting Efforts Of BLA Consultant, Parexel In Preparation For Chemistry, Manufacturing, Controls Filing

Financial news for AMPE dated on 2018-05-14: UPDATE: Ampio Says FDA Discussions Ongoing Related To Development Process Prior To Filing Of BLA

Financial news for AMPE dated on 2018-05-14: UPDATE: Ampio Pharma Reports Received Total Of \$3.1M From Investor Warrants, Stock Options Being Exercised In Q1

Financial news for AMPE dated on 2018-05-14: Ampio Provides Company Update

Financial news for AMPE dated on 2018-05-01: 36 Biggest Movers From Yesterday

Financial news for AMPE dated on 2018-04-12: Ampio Pharma Says Received Notification Letter From NYSE Confirming Co. Now In Full Compliance With Listing Requirements

Financial news for AMPE dated on 2018-04-12: Ampio Pharma Says Has Begun Prelim. Discussions With FDA On Details OF BLA Submission Process For Ampion

Financial news for AMPE dated on 2018-04-12: 'Ampio Pharmaceuticals: Cash Critically Low, Pattern Of Exaggerated Claims Continues'

Financial news for AMPE dated on 2018-04-11: 36 Biggest Movers From Yesterday

Financial news for AMPE dated on 2018-04-10: 25 Stocks Moving In Tuesday's Mid-Day Session

Financial news for AMPE dated on 2018-03-23: 41 Biggest Movers From Yesterday

Financial news for AMPE dated on 2018-03-15: Ampio Pharma Says AP-003-C Showed Primary Endpoint Achieved Statistical Significance , Ampion Was Statistically Superior

Financial news for AMPE dated on 2018-02-21: 40 Biggest Movers From Yesterday

Financial news for AMPE dated on 2018-02-20: Ampio Pharma Shares Down 10.5% Tues., Continuing 14% Decline From Fri.; Not Seeing News To Justify Price Action; Earlier Saw Several Bearish Option Alerts: Mar. \$2, \$4 Puts Saw Notable Activity

Financial news for AMPE dated on 2018-02-20: Ampio Pharma Option Alert: Mar 16 \$4 Puts Sweep (26) at the Ask: 500 @ \$1.4 vs 11 OI; Ref=\$2.7501

Financial news for AMPE dated on 2018-02-20: 45 Biggest Movers From Friday

Financial news for AMPE dated on 2018-02-16: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for AMPE dated on 2018-01-05: 36 Biggest Movers From Yesterday

Financial news for AMPE dated on 2018-01-04: 33 Stocks Moving In Thursday's Mid-Day Session

Financial news for AMPE dated on 2018-01-04: Adam Feuerstein Tweets (2/2): They're the black hole of credibility. But hey, other than that, it's great!

Financial news for AMPE dated on 2018-01-04: Adam Feuerstein Tweets (1/2): Yet, \$AMPE data collected to date demonstrates Ampion does not help people bc it lacks potency. And management carries significant credibility deficit.

Financial news for AMPE dated on 2018-01-04: 40 Biggest Movers From Yesterday

Financial news for AMPE dated on 2018-01-03: 35 Biggest Movers From Yesterday

Financial news for AMPE dated on 2018-01-02: Ampio Pharma Shares Resume Trade, Continue Lower, Now Down 28.2% For Session

Financial news for AMPE dated on 2018-01-02: Ampio Pharma Shares Halted On Circuit Breaker, Down 24.7% For Session; Downside Intensified As \$3.50 Support Level Was Broken

Financial news for AMPE dated on 2018-01-02: 28 Stocks Moving In Tuesday's Mid-Day Session

Financial news for AMPE dated on 2018-01-02: STAT News' Adam Feuerstein Tweets: With an arthritis drug no better than common saline, \$AMPE shot at FDA approval is dim statnews.com/2018/01/02/art... The bear thesis, explained.

Financial news for AMPE dated on 2018-01-02: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for AMPE dated on 2017-12-29: 32 Biggest Movers From Yesterday

Financial news for AMPE dated on 2017-12-28: 31 Stocks Moving In Thursday's Mid-Day Session

Financial news for AMPE dated on 2017-12-27: 32 Biggest Movers From Yesterday

Financial news for AMPE dated on 2017-12-26: 30 Stocks Moving In Tuesday's Mid-Day Session

Financial news for AMPE dated on 2017-12-19: 36 Stocks Moving In Tuesday's Mid-Day Session

Financial news for AMPE dated on 2017-12-19: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for AMPE dated on 2017-12-19: 40 Biggest Movers From Yesterday

Financial news for AMPE dated on 2017-12-14: Ampio Pharma Reports Results For Primary, Secondary Endpoints Of Phase 3 Trial Of Ampion In Severe OAK

Financial news for AMPE dated on 2017-11-24: 40 Biggest Movers From Wednesday

Financial news for AMPE dated on 2017-11-22: 35 Stocks Moving In Wednesday's Mid-Day Session

Financial news for AMPE dated on 2017-11-22: Ampio Pharma Shares Indicated Higher Following Release Highlighting Publication Of Co.'s Treatment For Sever Osteoarthritis Of The Knee

Financial news for AMPE dated on 2017-11-15: Ampio Pharma Reports Commencement Of Open Label Extension Study For Support Of Commercial Label Of Repeat Administration Of Ampion

Financial news for AMPE dated on 2017-10-17: 35 Biggest Movers From Yesterday

Financial news for AMPE dated on 2017-10-16: 30 Stocks Moving In Monday's Mid-Day Session

Financial news for AMPE dated on 2017-10-16: Asterias Biotherapeutics Prices

Registered Direct Offering at \$2.60/Share

Financial news for AMPE dated on 2017-10-16: Amio Pharma Prices \$6.75M Registered Direct Offering at \$0.875/Share

Financial news for AMPE dated on 2017-10-12: Ampio Pharma Reports Acceptance Of Pooled Ampion Trial Results In Patients With Severe Osteoarthritis Of The Knee

Financial news for AMPE dated on 2017-09-07: Ampio Recieves Non-compliance Listing Notice From NYSE, Has Until 3/1/19 To Regain Compliance

Financial news for AMPE dated on 2017-08-08: Ampio Pharma Reports Allowance Of Important Composition, Methods Patent In USA Complimenting Series Of Patents On Ampion (127 Issued, 80 Pending)

Financial news for AMPE dated on 2017-06-22: Ampio Injects Initial Patient in Final Pivotal Clinical Trial for Ampion BLA

Financial news for AMPE dated on 2017-06-12: Ampio Pharma Announces Will Not Renew Contract Of Gregory Gould; Tom Chilcott Named As Interim CFO

Financial news for AMPE dated on 2017-06-02: Ampio Pharma Reports Pricing of \$6.3M Common Stock, Warrants Offering at Combined Price of \$0.60/Share

Financial news for AMPE dated on 2017-05-01: Ampio Starts Pivotal Trial of Ampion

Financial news for AMPE dated on 2017-03-28: Ampio Pharma Reports Waiver, Consent Letter Deal with CVI Investments

Financial news for AMPE dated on 2017-03-20: Ampio Announces Locust Walk Will Serve as Strategic Advisor to Co.

Financial news for AMPE dated on 2017-03-20: UPDATE: Ampio Says Plans to Advance All Necessary BLA Activities in Parallel to Expedite Path to Potential FDA Approval

Financial news for AMPE dated on 2017-03-20: Ampio Pharma Says FDA's Responder Rate Definition Would Have All Previous Ampion Single Injections Trials Successfully Meeting Trial Endpoint

Financial news for AMPE dated on 2017-02-27: Ampio Receives Guidance from the FDA and Proposes a Path for Approval for Single-Injection Ampion, Proposed Pre-Approval Study

Financial news for AMPE dated on 2016-10-04: Ampio Pharma Reports Publication of Manuscript Covering 'Low Dose Danazol in Combination With Renin Angiotensin Inhibitors' Accepted for Acta Ophthalmologica

Financial news for AMPE dated on 2016-09-29: Ampio Pharma Reports Completion Of Enrollment For AP-011 Study

Financial news for AMPE dated on 2016-09-08: Ampio Reports Peer-Reviewed Publication on the Potential use of Ampion in New Clinical Indications

Financial news for AMPE dated on 2016-09-07: CVI Investments Reports 8.8% Passive Stake in Ampio Pharmaceuticals in 13G

Financial news for AMPE dated on 2016-08-29: Ampio Reports Pricing Of 5M Registered Shares In Direct Offering

Financial news for AMPE dated on 2016-08-03: Ampio Pharmaceuticals Files Meeting Request And Briefing Document With FDA To Seek Guidance On BLA For Ampion

Financial news for AMPE dated on 2016-06-30: Mid-Afternoon Market Update: Dow Rises More Than 200 Points; Care.com Shares Gain Following Alphabet Investment

Financial news for AMPE dated on 2016-06-30: 10 Biggest Mid-Day Losers For Thursday

Financial news for AMPE dated on 2016-06-30: Ampio Pharma Reports Will Request FDA Approval for Treatment of Pain Due to Severe Osteoarthritis of the Knee

Financial news for AMPE dated on 2016-05-03: Ampio Reports Additional Peer-Reviewed Publications on Ampion

Financial news for AMPE dated on 2016-03-01: Knoll Capital Management Reports 6.5% Stake in Ampio Pharmaceuticals in 13G

Financial news for AMPE dated on 2015-11-02: Ampio Intends to Distribute Aytu BioScience Stock to Ampio Shareholders

Financial news for AMPE dated on 2015-10-14: Ampio Pharmaceuticals, Inc. Announces

Updates On the Regulatory Path for FDA Approval of Optina(tm), an Oral Treatment for Diabetic Macular Edema (DME)

Financial news for AMPE dated on 2015-10-13: 8-K from Ampio Pharma Shows nit Aytu Bioscience Entered MSA with Biovest Int'l for Providing of Manufacturing Services to Aytu

Financial news for AMPE dated on 2015-09-22: Morning Market Gainers

Financial news for AMPE dated on 2015-09-22: AMPIO Receives Special Protocol Assessment from FDA; Commences Second Phase III pivotal trial of Ampion

Financial news for AMPE dated on 2015-09-08: Adam Feuerstein @adamfeuerstein Given the \$FLXN blow up, \$AMPE should trade at zero. Literally, zero.

Financial news for AMPE dated on 2015-08-22: Costa: 7 Stocks Market Technicians Should Keep An Eye On

Financial news for AMPE dated on 2015-06-22: Ampio Pharmaceuticals Reports Additional Statistically Significant Study Results for Optina in the Treatment of Diabetic Macular Edema

Financial news for AMPE dated on 2015-06-09: Ampio Pharmaceuticals Announces Synergistic Effects Of Ampion

Financial news for AMPE dated on 2015-05-27: 8-K from Ampio Pharma Shows Co. Has Purchased Jazz Pharma's ProstaScint for \$1M at Closing Plus Added \$500K Payable Within Five Days After Transfer

Financial news for AMPE dated on 2015-05-21: Ampio CMO Says Optina Results Not Significant

Financial news for AMPE dated on 2015-05-21: Morning Market Gainers

Financial news for AMPE dated on 2015-05-21: Ampio Pharmaceuticals Reports Positive Study Results on Optina For Treatment of Diabetic Macular Edema

Financial news for AMPE dated on 2015-04-20: Morning Market Losers

Financial news for AMPE dated on 2015-04-20: Ampio Pharmaceuticals Shares Fall 46% Premarket Following Announcement of Failure of STRIDE Study AP008 to Reach Primary Endpoint

Financial news for AMPE dated on 2015-04-20: UPDATE: Ampio Pharmaceuticals Multiple-Injection STRIDE Study AP008 Did Not Reach Primary Endpoint Against Saline Control

Financial news for AMPE dated on 2015-04-20: AMPIO Announces Ampion STRIDE Study Results

Financial news for AMPE dated on 2015-01-27: Ampio Pharmaceuticals Shares Move Lower; May be Attributed to Seeking Alpha Post

Financial news for AMPE dated on 2014-12-01: Ampio Announces Results Of The Open Label Portion Of The Multiple Intra-articular Injections Study Of Ampion In Patients With Osteoarthritis Of The Knee At Week Twenty Of The Trial

Financial news for AMPE dated on 2014-10-16: Ampio Announces Results of the Open Label Portion of the Multiple Intra-articular Injections Study of Ampion

Financial news for AMPE dated on 2014-09-03: Ampio Shares Move Lower; May be Attributed to Negative Adam F/Street.com Article

Financial news for AMPE dated on 2014-09-02: Ampio Offers Update on Phase III Multicenter, Double-Blind STEP Study of Ampion

Financial news for AMPE dated on 2014-08-25: Ampio Pharma Announces Responses to Questions Related to STEP Study

Financial news for AMPE dated on 2014-08-22: Morning Market Losers

Financial news for AMPE dated on 2014-08-22: Benzinga's Top Downgrades

Financial news for AMPE dated on 2014-08-22: Jefferies Downgrades Ampio Pharmaceuticals To Hold

Financial news for AMPE dated on 2014-08-22: Jefferies Downgrades Ampio Pharmaceuticals, Inc. to Hold, Lowers PT to \$5.00

Financial news for AMPE dated on 2014-08-21: Morning Market Losers

Financial news for AMPE dated on 2014-08-21: Ampio Says Release of Data Will Be Delayed, FDA Agreed to Analyze Step Trial As Supportive Data for BLA

Financial news for AMPE dated on 2014-08-05: Ampio Announces Positive Results From Multiple Injection Study

Financial news for AMPE dated on 2014-07-30: Ampio Pharma Says FDA Gave Positive Response Regarding Starting Production of Ampion in New Facility

Financial news for AMPE dated on 2014-06-27: Jefferies Initiates Coverage on Ampio Pharmaceuticals, Inc. at Buy, Announces \$14.00 PT

Financial news for AMPE dated on 2014-06-25: Adam Feuerstein Tweet: \$AMPE Expects Investors to Wear Beer Goggles Before Reading Eye-Drug Press Release --> thestreet.com/story/12756754

Financial news for AMPE dated on 2014-06-25: Ampio Pharma Announces Closing of Enrollment in OptimEyes Study, Cites Positive Feedback

Financial news for AMPE dated on 2014-06-05: Ampio Announces Gregory Gould CFO

Financial news for AMPE dated on 2014-04-10: Ampio Pharmaceuticals' Vyrix Enters into an Agreement with Paladin Labs for Exclusive Rights to Zertane in Canada

Financial news for AMPE dated on 2014-04-09: Ampio Pharma to Present Results of 20 Weeks Extension of Ampion SPRING Study at Western Orthopedic Association

Financial news for AMPE dated on 2014-03-05: Ampio Pharma Closes Sale of 9.775M Shares of Stock, Sees Net Proceeds ~\$63.3M

Financial news for AMPE dated on 2014-02-28: UPDATE: Ampio Pharmaceuticals Shares Fall 7% Premarket on Pricing of 8M Share Offering at \$7.00

Financial news for AMPE dated on 2014-02-27: Ampio Pharmaceuticals Prices 8.5M Share Offering at \$7.00/Share

Financial news for AMPE dated on 2013-12-26: Ampio Pharma Files \$100M Mixed Securities Shelf

Financial news for AMPE dated on 2013-12-13: Ampio Pharmaceuticals Spins-Off Sexual Dysfunction Business

Financial news for AMPE dated on 2013-12-02: Ampio Pharma Receives FDA Confirmation Spring Study is Pivotal, Will Begin the Final Pivotal Trial for Ampion BLA

Financial news for AMPE dated on 2013-11-25: Ampio Hides Need For New Eye Drug Study in SEC Filing -Adam F/The Street

Financial news for AMPE dated on 2013-10-07: Ampio Pharma Announces Results from Panel Review of the Interim Analysis of the Optina(TM) Trial, FDA Agrees to 505(B) 2 Pathway

Financial news for AMPE dated on 2013-09-30: Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial

Financial news for AMPE dated on 2013-08-15: Top Double Digit Winners and Losers From Wednesday, August 14, 2013

Financial news for AMPE dated on 2013-08-14: Morning Market Movers

Financial news for AMPE dated on 2013-08-14: Ampio Pharmaceuticals Announces Ampion Study Meets Primary Endpoint with High Statistical Significance; All Primary Study Objectives were Achieved

Financial news for AMPE dated on 2013-08-07: Ampio Responds to Street.com Article

Financial news for AMPE dated on 2013-08-06: Ampio Pharmaceuticals Spikes Lower; May be Attributed to Adam F/Street.com Article

Financial news for AMPE dated on 2013-06-20: Ampio Pharma's Luoxis Diagnostics Reports Positive Results from First Study of Proprietary Diagnostic Platform

Financial news for AMPE dated on 2013-06-05: Afternoon Market Losers

Financial news for AMPE dated on 2013-04-25: Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the Knee

Financial news for AMPE dated on 2013-04-02: A Peek Into The Market Before The Trading Starts

Financial news for AMPE dated on 2013-04-02: Ampio Receives FDA Acceptance for Clinical Trial of Ampion for Treatment of Osteoarthritis of the Knee

Financial news for AMPE dated on 2013-03-11: Benzinga's Small Cap Movers for Monday March 11, 2013

Financial news for AMPE dated on 2013-03-04: UPDATE: Aegis Capital Reiterates Buy Rating, Raises PT on Ampio Pharmaceuticals on Clinical Milestones

Financial news for AMPE dated on 2013-03-01: Aegis Capital Maintains Buy on Ampio Pharmaceuticals, Inc., Raises PT to \$12.00

Financial news for AMPE dated on 2013-02-27: Ampio Pharmaceuticals Begins Clinical Trial of Optina for Diabetic Macular Edema

Financial news for AMPE dated on 2013-02-25: A Peek Into The Market Before The Trading Starts

Financial news for AMPE dated on 2013-02-25: Ampio Pharmaceuticals Announces Phase 3 Ampion Study for Osteoarthritis of the Knee to Include a Dose-Escalation Run-in Study

Financial news for AMPE dated on 2013-01-22: A Peek Into The Market Before The Trading Starts

Financial news for AMPE dated on 2013-01-22: FDA Accepts Ampio Pharmaceuticals IND for Optina for Treatment of Diabetic Macular Edema

Financial news for AMPE dated on 2012-08-28: Negative Seeking Alpha Article on Ampio Pharmaceuticals

Financial news for AMPE dated on 2012-08-24: Ampio Pharmaceuticals Rises 18% on Positive Motley Fool Report on Thursday

Financial news for AMPE dated on 2012-07-16: Ampio Advances NCE001 Cancer Drug into Preclinical Development Following Successful Recent Financing and the Granting of Patents in USA, Canada, Europe and China

Financial news for AMPE dated on 2012-07-13: From Earlier: Ampio Pharmaceuticals Announces Pricing of Public Offering of 4,6M Shares at \$3.25

Financial news for AMPE dated on 2012-07-03: Ampio's CEO and CSO Send Message to Shareholders

Financial news for AMPE dated on 2012-07-02: Ampio Pharmaceuticals Spokesperson Confirms Seeking Alpha's Richard Cavalli Was Flown Out to Company Headquarters

Financial news for AMPE dated on 2012-07-02: Morning Market Movers

Financial news for AMPE dated on 2012-07-02: Ampio Contracts with Syngene to Manufacture Zertane-ED, its Recently Patented Combination Drug

Financial news for AMPE dated on 2012-06-21: From Earlier: Ampio Reports Successful Type B Pre-IND Meeting with the FDA for its Drug Zertane(tm) to treat Premature Ejaculation (PE)

Financial news for AMPE dated on 2012-06-11: These 5 Small Cap Stocks Are Up Better Than 10% Today

Financial news for AMPE dated on 2012-06-11: Ampio Pharmaceuticals Rises 23% on Positive Clinical Trial Results for Optina

Financial news for AMPE dated on 2012-06-11: Benzinga's Top Pre-Market Gainers

Financial news for AMPE dated on 2012-06-11: From Earlier: Ampio Announces Positive Clinical Trial Results for the Treatment of Diabetic Macular Edema with Orally Administered Optina(tm)

Financial news for AMPE dated on 2012-05-11: Ampio Pharmaceuticals Reports Pre-IND Meeting With the FDA to Obtain Clinical Path Guidance for Ampion

Financial news for AMPE dated on 2012-05-11: A Peek Into The Market Before The Trading Starts

Financial news for AMPE dated on 2012-05-11: Ampio Pharmaceuticals Reports Pre-IND Meeting With the FDA to Obtain Clinical Path Guidance for Ampion

Financial news for AMPE dated on 2012-04-27: Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina for the treatment of Diabetic Macular Edema

Financial news for AMPE dated on 2012-04-09: A Peek Into The Market Before The Trading Starts

Financial news for AMPE dated on 2012-04-09: Ampio Submits Type B Pre IND Meeting Request to the FDA for Zertane(tm)

Financial news for AMPE dated on 2012-04-02: Ampio Reaches Agreement with the TGA for the Submission Plan for Zertane in Australia

Financial news for AMPE dated on 2012-03-22: Ampio Pharmaceuticals Announces the Licensing of Zertane to FBM Industria Farmaceutica Ltda to Commercialize in Brazil

Financial news for AMPE dated on 2012-03-20: Monday's NASDAQ Winners: RCON, AMPE, SAPX, AGEN

Financial news for AMPE dated on 2012-03-20: Ampio Strengthens Patent Protection for Lead Drug Ampion

Financial news for AMPE dated on 2012-03-19: Why Ampio's Rebound Run May Not Be Done

Financial news for AMPE dated on 2012-03-19: Ampio Pharma Soars 45% on Positive Clinical Trial

Financial news for AMPE dated on 2012-03-19: Morning Market Movers

Financial news for AMPE dated on 2012-01-31: Hedge Fund Shkreli: Ampio Pharmaceuticals PR this Morning is "Laughable"

Financial news for AMPE dated on 2012-01-31: Ampio Pharmaceuticals Announces Statistically Significant Improvement in Pain Relief for its Lead Product, Ampion in the Osteoarthritis of the Knee Trial.

Financial news for AMPE dated on 2012-01-26: Scorecard and New Picks: Technical Value Fishing Under \$5

Financial news for AMPE dated on 2012-01-09: Ampio CEO Taking Compassionate Leave

Financial news for AMPE dated on 2012-01-03: Ampio Pharmaceuticals Completes Expanded Patient Enrollment for Ampion In Osteoarthritis of the Knee Clinical Trial in Australia

Financial news for AMPE dated on 2011-12-22: Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion

Financial news for AMPE dated on 2011-12-21: Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately \$9.436M

Financial news for AMPE dated on 2011-12-16: Ampio Says Factually Inaccurate and Purposely Misleading Information Panicked Market

Financial news for AMPE dated on 2011-12-16: Ampio Responds to What May Be a Coordinated Short Selling Attack Against the Firm's Stock

Financial news for AMPE dated on 2011-12-16: Ampio Responds to Recent Publications by Anonymous Short Sellers

Financial news for AMPE dated on 2011-12-05: Ampio Pharmaceuticals Announces Agreement to Acquire Key Drug Delivery Technology

Financial news for AMPE dated on 2011-11-10: Financial Breakfast: Morning News Summary for November 10, 2011

Financial news for AMPE dated on 2011-11-10: Ampio Pharmaceuticals Announces Positive Results on Ampion Trial for Relief of Nasal Inflammation

Financial news for AMPE dated on 2011-10-18: Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina

Financial news for AMPE dated on 2011-10-13: Ampio Pharmaceuticals Completes Treatment Phase of the Ampion-in-Knee Clinical Trial for Osteoarthritis

Financial news for AMPE dated on 2011-10-10: Ampio Announces the Presentation of a Publication on Ampion, its Drug Candidate to Address Human Inflammation

Financial news for AMPE dated on 2011-09-28: Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane with Erectile Dysfunction Drugs in Canada

Financial news for AMPE dated on 2011-09-08: Ampio Pharmaceuticals' Executes License and Development Agreement with Daewoong to Commercialize Zertane in South Korea

Financial news for AMPE dated on 2011-08-30: Zertane Clinical Results Published in the Journal European Urology

Financial news for AMPE dated on 2011-08-22: Ampio Pharmaceuticals Announces Hiring of Deborah Knobelman as Chief Business Officer

Financial news for AMPE dated on 2011-07-05: Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee Trial for Osteoarthritis in Australia

Financial news for AMPE dated on 2011-06-27: Ampio Pharmaceuticals Releases Results From Phase III Clinical Trial of Zertane for the Treatment of Premature Ejaculation

Financial news for AMPE dated on 2011-05-31: Ampio Pharmaceuticals Announces Initiation of Phase 1B Clinical Trial for Its Anti-inflammatory Drug Ampion